ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 92 | 97 | +5 |
| Shares | 55.1M | 66.5M | +11.5M (+20.8%) |
| Value | $369.0M | $251.6M | −$117.4M (−31.8%) |
New holders (23)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Charles Schwab Trust Co | 4,246,071 | $16.1M | 1.81% |
| Franklin Resources Inc | 3,868,509 | $14.6M | 0.01% |
| Soleus Capital Management, L.P. | 150,000 | $567.0K | 0.06% |
| Group One Trading, L.P. | 111,071 | $419.8K | 0.02% |
| Virtu Financial LLC | 80,816 | $305.0K | 0.03% |
| Letko, Brosseau & Associates Inc | 36,000 | $136.1K | 0.00% |
| Creative Planning | 27,931 | $105.6K | 0.00% |
| Simplex Trading, LLC | 26,151 | $98.0K | 0.00% |
| Bank of Montreal | 13,835 | $97.5K | 0.00% |
| Brendel Financial Advisors LLC | 19,125 | $72.0K | 0.11% |
| UBS Asset Management Americas Inc | 12,940 | $48.9K | 0.00% |
| StoneX Group Inc. | 11,280 | $42.6K | 0.00% |
| ExodusPoint Capital Management, LP | 11,030 | $42.0K | 0.00% |
| XTX Topco Ltd | 10,117 | $38.2K | 0.01% |
| CI Private Wealth, LLC | 10,042 | $38.0K | 0.00% |
| Belvedere Trading LLC | 6,143 | $23.2K | 0.00% |
| Salomon & Ludwin, LLC | 2,785 | $10.5K | 0.00% |
| Park Circle Co | 2,000 | $7.56K | 0.01% |
| Federated Hermes, Inc. | 707 | $2.67K | 0.00% |
| Lindbrook Capital, LLC | 209 | $790 | 0.00% |
| Parallel Advisors, LLC | 151 | $571 | 0.00% |
| Nisa Investment Advisors, LLC | 25 | $95 | 0.00% |
| CWM, LLC | 18 | $0 | 0.00% |
Sold out (18)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Nicholas Investment Partners, LP | 275,000 | $1.84M |
| Norges Bank | 243,100 | $1.63M |
| Two Sigma Advisers, LP | 226,800 | $1.52M |
| Resolute Capital Asset Partners LLC | 140,000 | $938.0K |
| Jump Financial, LLC | 111,900 | $749.7K |
| Squarepoint Ops LLC | 84,808 | $568.2K |
| Marshall Wace, LLP | 74,621 | $500.0K |
| Caption Management, LLC | 73,400 | $491.8K |
| Shell Asset Management Co | 65,322 | $438.0K |
| Jefferies Financial Group Inc. | 60,190 | $403.3K |
| Eversept Partners, LP | 48,788 | $326.9K |
| Jacobs Levy Equity Management, Inc | 37,903 | $253.9K |
| DekaBank Deutsche Girozentrale | 35,000 | $231.0K |
| Fox Run Management, L.L.C. | 22,992 | $154.0K |
| Bridgeway Capital Management, LLC | 19,944 | $133.6K |
| Price T Rowe Associates Inc | 16,537 | $111.0K |
| Stifel Financial Corp | 12,327 | $82.6K |
| Aquatic Capital Management LLC | 6,900 | $46.0K |